Kimer Med update Oct 2022

Greetings from Kimer Med.

From the lab:

Things are progressing well on the science front. We currently have multiple strands of experimentation underway, which is keeping us all very busy.

CEO, Rick Kiessig (seated) and Business Development Manager, Mike Schmidt take a look at some cells on our fluorescence-capable EVOS M5000 Imaging System.

Update on the Monkeypox outbreak:
The current monkeypox outbreak continues to cause concern around the globe, not least because there are no specific antivirals to treat it. As attempts are being made to rapidly repurpose other drugs in the hope that they might prove to be effective, the situation highlights just how vital our work to develop a broad-spectrum antiviral is.

Monkeypox is an infectious disease caused by the monkeypox virus (MPX), for which there is currently no known cure. Numbers infected are approaching 60,000 and more than 22 deaths have been confirmed so far.

Drug repurposing and the quest for a cure
Because monkeypox is in the same genus as the virus that causes smallpox, some scientists have turned to antiviral drugs and vaccines that were used on smallpox, as well as a range of other drugs, to see if they can find a cure or preventative treatment.

One group of researchers in Japan employed a drug repurposing approach, identifying 132 already-approved drugs and testing them for activity against monkeypox. The list of candidates included antiviral, anti-fungal, and anti-parasitic agents. It’s not clear yet whether this work will result in a specific and effective treatment for Monkeypox.

As always, thanks for your interest in our work.
Until next time,

The team at Kimer Med